LMAT
LEMAITRE VASCULAR INC
Next earnings Aug 3, 2026 · consensus $0.82 EPS, $72.9M rev
Last earnings +0.4% on 2026-05-05
$95.66
▲ +1.84%$95.66▲ +15.78%
over 1Y
L $79.04EODHDH $117.10
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+1.8%
1W+8.0%
1M-0.1%
3M-10.1%
YTD+19.9%
1Y+15.8%
Buy
Conviction
Horizon
Medium (3–12mo)
Street · 15 analysts
Buy
Revenue grew 13.5% YoY.
Revenue (FY2025) $250M · FY2025
The read
Solid fundamentals at a roughly fair price — reasonable risk/reward at today's level.
LEMAITRE VASCULAR INC shows $250M in FY2025 revenue (+13.5% YoY), a 23.1% net margin, and 14.7% ROE.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $154M | $162M | $193M | $220M | $250M |
| Gross profit | $101M | $105M | $127M | $151M | $179M |
| Operating income | $36.4M | $26.8M | $36.7M | $52.3M | $67.9M |
| Net income | $26.9M | $20.6M | $30.1M | $44.0M | $57.7M |
| Diluted EPS | $1.25 | $0.93 | $1.34 | $1.93 | $2.52 |
| Net margin | 17.4% | 12.8% | 15.6% | 20.0% | 23.1% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$2.15B
EV / EBITDA27.5
EV / Sales8.6
EV / FCF28.9
P / FCF29.3
PEG (trailing)1.22
Earnings yield2.6%
FCF yield3.4%
Quality & risk
ROIC (est.)13.6%
Free cash flow$74.5M
Total debt—
Net cash$28.2M
Altman Z-Score7.92 safe
Piotroski F-Score6/8
Capital returns
Buyback yield0.1%
Dividend yield (est.)0.8%
Shareholder yield0.9%
Shares Δ YoY+1.0%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsSome governance/structural items recently, but no outright red flags.
Recent filings
all on EDGAR ↗4Period ending 2026-06-042026-06-05open ↗4Period ending 2026-06-042026-06-05open ↗4Period ending 2026-06-042026-06-05open ↗4Period ending 2026-06-042026-06-05open ↗4Period ending 2026-06-042026-06-05open ↗4Period ending 2026-06-042026-06-05open ↗4Period ending 2026-06-042026-06-05open ↗4Period ending 2026-06-042026-06-05open ↗4Period ending 2026-06-042026-06-05open ↗8-KPeriod ending 2026-06-022026-06-05open ↗SDFiling2026-05-29open ↗SCHEDULE 13G/AFiling2026-05-14open ↗
Frequently asked
- Is LEMAITRE VASCULAR INC (LMAT) a buy?
- LMAT currently carries a Buy rating with 4/5 conviction, derived from its latest SEC filings. Revenue grew 13.5% YoY.
- What is LMAT's fair value?
- A Modified-Graham model based on LMAT's SEC fundamentals estimates a fair value of about $95.76. It is an estimate from reported earnings, not a price target.
- Is LMAT overvalued or undervalued?
- Against a Modified-Graham fair-value estimate, LMAT currently appears fairly valued relative to its SEC-grounded earnings power.
- What is LEMAITRE VASCULAR INC's quality score?
- LMAT scores 75.33333333333333/100 (grade B+) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001158895, latest 10-Q filed 2026-05-06) · EODHD · as of 6/26/2026, 7:04:14 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.